  |
3GCI |
Crystal Structure of the Complex Formed Between a New Isoform of Phospholipase A2 with C-terminal Amyloid Beta Heptapeptide at 2 A Resolution |
P |
A |
|
 |
  |
3FUR |
Crystal Structure of PPARg in complex with INT131 |
H |
A |
|
|
  |
3FII |
Crystal structure of Clostridium botulinum neurotoxin serotype F catalytic domain with an inhibitor (inh2) |
B |
A |
|
|
  |
3FIE |
Crystal structure of Clostridium botulinum neurotoxin serotype F catalytic domain with an inhibitor (inh1) |
C |
A |
|
|
  |
3CPL |
Crystal Structure of H-2Db in complex with a variant M6A of the NP366 peptide from influenza A virus |
E |
A |
|
|
  |
3C2G |
Crystal complex of SYS-1/POP-1 at 2.5A resolution |
C |
A |
|
|
  |
3BWA |
Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein |
C |
A |
MHC antigen-recognition domain |
|
  |
3BW9 |
Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein |
C |
A |
MHC antigen-recognition domain |
|
  |
2QV1 |
Crystal structure of HCV NS3-4A V36M mutant |
C |
DAB |
|
|
  |
2PQ2 |
Structure of serine proteinase K complex with a highly flexible hydrophobic peptide at 1.8A resolution |
B |
A |
Subtilisin-like |
|
  |
2OIN |
crystal structure of HCV NS3-4A R155K muntant |
C |
DAB |
|
|
  |
2NWN |
New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-type Plasminogen Activator Complexed with a Cyclic Peptidyl Inhibitor, upain-1 |
B |
A |
|
|
  |
2DS2 |
Crystal structure of mabinlin II |
A |
BD |
|
|
  |
1YK0 |
structure of natriuretic peptide receptor-C complexed with atrial natriuretic peptide |
E |
A |
|
|
  |
1VGK |
The crystal structure of class I Major histocompatibility complex, H-2Kd at 2.0 A resolution |
C |
A |
MHC antigen-recognition domain |
|
  |
1SKG |
Structure-based rational drug design: Crystal structure of the complex formed between Phospholipase A2 and a pentapeptide Val-Ala-Phe-Arg-Ser |
B |
A |
Phospholipase A2. PLA2 |
|
  |
1R5V |
Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T-cell activation |
E |
AB |
MHC antigen-recognition domain |
|
  |
1Q3P |
Crystal structure of the Shank PDZ-ligand complex reveals a class I PDZ interaction and a novel PDZ-PDZ dimerization |
C |
A |
PDZ domain-like |
|
  |
1MUJ |
Crystal structure of murine class II MHC I-Ab in complex with a human CLIP peptide |
C |
AB |
MHC antigen-recognition domain |
|
  |
1KL3 |
an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm1-StrepII |
E |
AD |
Streptavidin-like |
|
  |
1KL5 |
an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm2-StrepII |
E |
AD |
Streptavidin-like |
|
  |
1K8D |
crystal structure of the non-classical MHC class Ib Qa-2 complexed with a self peptide |
P |
A |
MHC antigen-recognition domain |
|
  |
1K2D |
Crystal structure of the autoimmune MHC class II I-Au complexed with myelin basic protein 1-11 at 2.2A |
P |
AB |
MHC antigen-recognition domain |
|
  |
1JDP |
Crystal Structure of Hormone/Receptor Complex |
H |
BA |
Periplasmic binding protein-like I |
|
  |
1A94 |
STRUCTURAL BASIS FOR SPECIFICITY OF RETROVIRAL PROTEASES |
C |
AB |
Acid proteases |
|
  |
1A8K |
CRYSTALLOGRAPHIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE WITH AN ANALOG OF THE CONSERVED CA-P2 SUBSTRATE: INTERACTIONS WITH FREQUENTLY OCCURRING GLUTAMIC ACID RESIDUE AT P2\' POSITION OF SUBSTRATES |
C |
AB |
Acid proteases |
|
